Short Bowel Syndrome - Pipeline Insight, 2025

DelveInsight’s, “Short Bowel Syndrome - Pipeline Insight, 2025,” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Short Bowel Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Short Bowel Syndrome: Understanding

Short Bowel Syndrome: Overview

Short bowel syndrome (SBS) in adults is defined as less than 180 to 200 centimeters of remaining small bowel (normal length 275 to 850 cm) leading to the need for nutritional and fluid supplements. Short bowel syndrome may be classified as a cause or subcategory of intestinal failure. In rare cases, infants are born with a short bowel (congenital short bowel syndrome). Although these congenital cases are often associated with malrotation of the small intestine, the exact cause of congenital short bowel syndrome is unknown. The main cause of short bowel syndrome is surgery to remove a portion of the small intestine. This surgery can treat intestinal diseases, injuries, or birth defects. Some children are born with an abnormally short small intestine or with part of their bowel missing, which can cause short bowel syndrome. In infants, short bowel syndrome most commonly occurs following surgery to treat necrotizing enterocolitis, a condition in which part of the tissue in the intestines is destroyed

""Short Bowel Syndrome- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Short Bowel Syndrome pipeline landscape is provided which includes the disease overview and Short Bowel Syndrome treatment guidelines. The assessment part of the report embraces, in depth Short Bowel Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence in Short Bowel Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve in Short Bowel Syndrome.
• In April 2021, 9 Meters Biopharma entered into a collaboration with the Duke Clinical Research Institute (DCRI) to support the clinical development of 9 Meters' candidate NM-002, a proprietary long-acting GLP-1 agonist, currently in Phase 2 development for short bowel syndrome (SBS).

This segment of the Short Bowel Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Short Bowel Syndrome Emerging Drugs

• Glepaglutide: Zealand Pharma

Glepaglutide is a long-acting GLP-2 analog in development as a potential treatment option for short bowel syndrome (SBS). Glepaglutide is being developed as a liquid product in an autoinjector designed for subcutaneous administration, aimed to reduce, or eliminate, the need for parenteral support in people living with SBS. Currently the product is in Phase III stage of development for the treatment of Short Bowel Syndrome

Further product details are provided in the report……..

Short Bowel Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Short Bowel Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Short Bowel Syndrome

There are approx. 18+ key companies which are developing the therapies for Short Bowel Syndrome. The companies which have their Short Bowel Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Zealand Pharma

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Short Bowel Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Molecule Type

Products have been categorized under various Molecule types such as

• Peptide
• Protein
• Propylene glycols
• Cell Therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Short Bowel Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Short Bowel Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Short Bowel Syndrome drugs.

Short Bowel Syndrome Report Insights

• Short Bowel Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Short Bowel Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Short Bowel Syndrome drugs?
• How many Short Bowel Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Short Bowel Syndrome?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Short Bowel Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Short Bowel Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AstraZeneca
• VectivBio
• Zealand Pharma
• 9 Meters Biopharma
• Hanmi Pharmaceutical
• Adocia
• PhaseBio Pharmaceuticals
• Surrozen
• NorthSea Therapeutics

Key Products

• Benralizumab
• Apraglutide
• Glepaglutide
• Vurolenatide
• HM15912
• NM-002
• BioChaperone GLP-2
• GLP2-ELP
• Research programme: regenerative therapeutics
• SEFA-6179